Skip to main content
. 2019 Nov 14;1(1):vdz046. doi: 10.1093/noajnl/vdz046

Table 3.

Age-adjusted hazard ratios (HRs) of meningiomas of combined effects of prostate diagnosis and male-hormone interfering drug use

HR* (95% CI)
Background population controls not treated with MHID 1.00 (Ref)
Hospital diagnosis of prostate disease not treated with MHID 1.78 (1.57–2.01)
Hospital diagnosis of prostate disease treated with MHID 1.75 (1.43–2.15)

*HR, hazard ratio.

CI, confidence interval.

Male-hormone interfering drugs.